WO2010121600A2 - Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten - Google Patents
Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten Download PDFInfo
- Publication number
- WO2010121600A2 WO2010121600A2 PCT/DE2010/000453 DE2010000453W WO2010121600A2 WO 2010121600 A2 WO2010121600 A2 WO 2010121600A2 DE 2010000453 W DE2010000453 W DE 2010000453W WO 2010121600 A2 WO2010121600 A2 WO 2010121600A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- opioid
- pharmaceutical composition
- opioid antagonist
- particles
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Definitions
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising an opioid, preferably morphine, and an opioid antagonist, preferably naloxone. More particularly, the present invention relates to a pharmaceutical composition for the controlled release of the opioid antagonist in a particular area of the digestive system, continuously over a period of 30 minutes to 8 hours after oral administration. Furthermore, the present invention relates to a pharmaceutical composition comprising first particles with the opioid and second particles with the opioid antagonist, wherein the first and second particles are indistinguishable. Furthermore, the present invention relates to a pharmaceutical composition comprising a particle with the opioid and with the opioid antagonist.
- opioid-like is a chemically heterogeneous group of natural and synthetic substances that possess morphine-like properties and are active on opioid receptors, distinguishing endogenous opioids, which play a role in pain suppression
- opioid refers to opioids naturally occurring in opium, which are chemically alkaloids and which include morphine.
- opioids Unlike nonopioid analgesics, opioids exert their analgesic effects primarily in the central nervous system (CNS).
- CNS central nervous system
- the most common adverse effects of opioids are nausea, vomiting, dizziness and, especially if used for long periods, (spastic) constipations of the intestine.
- An overdose of opioids can lead to dangerous respiratory depression or suffocation.
- the opioids are in addition to the benzodiazepines to the substances that can cause a strong drug dependence.
- the anxiety-relieving and euphoric effects of opioids are primarily held responsible for the psychological component of dependency.
- the physical dependency is mainly due to the fact that it comes with withdrawal of opioid intake withdrawal symptoms, which is based on an increased release of norepinephrine. Typical withdrawal symptoms are restlessness, unfounded sensations of pain, depression, vomiting and stomach cramps, diarrhea, fatigue and flu-like symptoms.
- Therapeutic opioids include tilidine, tramadol and morphine. Tilidin is often not enough for very severe pain and morphine or morphine-like substances are used. Morphine (5R, 6S, 9R, ⁇ 3S, l4R) -4,5-epoxy-N-methylmorphin-7-ene-3,6-diol, also colloquially referred to as morphine, is a very effective analgesic derived from the Capsules of the opium poppy is obtained and has the following structural formula:
- the most analgesic opioids include sufentanil, remifentanil and fentanyl.
- Therapeutically insignificant is heroin (diacetylmorphine), whose release in Germany is prohibited.
- Heroin substitution therapy mainly uses the opioid methadone.
- intravenous (syringes), nasal (sniffing) or pulmonary (smoking) administration is preferred because of the rapid onset of action ("kick") over oral ingestion.
- a preparation is melted or dissolved and injected intravenously, or it is burned on aluminum foil and inhaled the smoke (foil smoking).
- opioid antagonists can be added to the pharmaceutical preparations.
- Such a commercial preparation is Valoron ® N, which contains a combination of tilidine and naloxone.
- Naloxone (5A, 9.K, 135.14S) -IT-AllyI-S, 14-dihydroxy-4,5-epoxymorphinan-6-one) is an opioid antagonist having the following structural formula:
- naloxone is one of the pure opioid antagonists that act as compeptive antagonists on all opioid receptors.
- Buprenorphine acts as a mixed agonist / antagonist at the ⁇ receptor.
- the antagonistic effect the effect of the opioid, i. of the agonist, suspended. This property is exploited by, for example, using naloxone therapeutically as an antidote in an opioid overdose.
- naloxone When administered orally naloxone is subject to a high first-pass effect, ie a substantial inactivation in the liver before reaching the site of action. On intravenous administration, on the other hand, large portions of the naloxone remain active. Since naloxone, as an opioid antagonist, abolishes the effect of the opiate, triggers simultaneous intravenous administration Opioid and opioid antagonist withdrawal syndrome. Naloxone can also exhibit its antagonistic effect on pulmonary, nasal, transdermal or rectal administration.
- a prerequisite for naloxone to fulfill its abuse protection function is that the opioid antagonist can not be readily separated from the opioid. This would be the case, for example, if the opioid and the opioid antagonist were administered with different tablets.
- a solvent for example water or ethanol
- a dosage form containing morphine containing a naltrexone core is known. Separation of morphine and naltrexone can be achieved by placing the dosage form in water for 20 minutes. Thereafter, the morphine is dissolved and can be obtained by abducting the naltrexone nuclei. There may also be a manual separation, for example by scraping or rupturing the outer shell of a preparation.
- WO 2007/082935 discloses dosage forms in which the opioid and the opioid antagonist are present as a powder or granule mixture. In the mixture, the particles containing the opioid and the opioid antagonist particles are visually indistinguishable. It is further disclosed that the opioid and / or the opioid antagonist can be released with a delay.
- naloxone exerts its desirable adverse effects substantially in non-oral administration, oral ingestion is not without side effects.
- active naloxone enters the colon, severe diarrhea lasting up to four weeks is elicited in patients who have developed constipation as a result of long-term opioid use.
- Valoron ® N is contraindicated in existing drug dependence of opiates.
- naloxone is easily absorbed in the mouth area.
- This principle is used for example in sublingual administration forms.
- the first-pass effect is at least partially circumvented, which is used in the administration of active ingredients through suppositories.
- naloxone to morphine, which is used to treat pain or as a substitution therapy, is highly problematic. In the extreme case, the therapy must be stopped.
- the object of the invention is achieved by a pharmaceutical composition
- a pharmaceutical composition comprising first particles and second particles, wherein the first particles comprise at least one opioid or a pharmaceutically acceptable salt thereof, and the second particles comprise at least one opioid antagonist or a pharmaceutically acceptable salt thereof wherein the first and second particles are indistinguishable by optically detectable and / or physical properties, characterized in that the release of the opioid antagonist is continuous over a period of 30 minutes to 8 hours after oral administration.
- the object of the invention is further achieved by a pharmaceutical composition
- a pharmaceutical composition comprising a particle comprising at least one opioid or a pharmaceutically acceptable salt thereof and at least one opioid antagonist or a pharmaceutically acceptable salt thereof, characterized in that the release of the opioid Antagonists are continuous over a period of 30 minutes to 8 hours after oral administration.
- the release of the opioid antagonist takes place continuously over a period of 30 Minutes to 6 hours, preferably from 45 minutes to 4.5 hours, after oral administration.
- the opioid is a full agonist, preferably morphine.
- the opiod antagonist has a bioavailability of less than 5%, and is preferably naloxone.
- the release of the opioid occurs for a period of from 0 to at least 12 hours, preferably from 0 to 24 hours after oral administration.
- the first and second particles are beads or the one particle are beads.
- the beads comprise a core and a controlled release coating.
- the coating for release of active ingredient comprises at least one polyacrylate / methacrylate Polyrner, in particular at least one Eudragit ®.
- a dosage form for peroral administration comprising one of the pharmaceutical compositions of the present invention for three times, preferably twice, more preferably once daily.
- the dosage form is a capsule, preferably a hard gelatin capsule, or a sachet.
- the ratio of opioid antagonist to opioid in the dosage form is less than 1:10, preferably in the range of 1: 250 to ⁇ 1:10, and most preferably 1: 100.
- the object of the invention is further achieved by a pharmaceutical composition of the present invention for use in the treatment of opioid dependence.
- the dose of the opioid in the dosage form is 200 mg. Accordingly, the dose of the antagonist is preferably 2 mg.
- the object of the invention is further achieved by a pharmaceutical composition of the present invention for pain therapy in opioid-dependent or non-opioid-dependent patients.
- the dosage of the opioid in the dosage form is 30 or 60 mg. Accordingly, the dose of the antagonist is preferably 0.3 or 0.6 mg.
- the opioid preferably morphine
- Preferred salts of morphine are morphine hydrochloride, morphine sulphate pentahydrate, morphine chlorate, morphine methobromide or other quaternary salts of morphine and morphine N-oxide. Particularly preferred is morphine sulfate pentahydrate.
- the opioid antagonist preferably naloxone
- the present invention provides more compatible pharmaceutical compositions with an opioid and an opioid antagonist which avoids the occurrence of withdrawal symptoms.
- This advantage is achieved by the particular release profile of opiod and opioid antagonist and by the relationship of these two to each other.
- the effect of the release profile is that unlike the Her usual concept of avoiding the "deprivation” also comes to avoid the so-called "local partial withdrawal” in the intestine.
- the pharmaceutical composition is formulated such that the opioid exhibits its beneficial effect while the effect of the opioid antagonist upon oral administration is substantially reduced or abolished.
- This property of the pharmaceutical composition i. better compatibility, is achieved by controlled release of the opioid antagonist, ie by release of the opioid antagonist in a specific area of the digestive system, while at the same time the release of the opioid is delayed ("delayed release"). sustained-release formulation). Since resorption of the opioid antagonist in the oral area avoids the first-pass effect, it is advantageous to prevent absorption in this section of the digestive system. According to the invention, this is achieved by virtually no release of the opioid antagonist takes place in the first 30 minutes after oral administration of the pharmaceutical composition (or in the presence of a physiological saline solution).
- the opioid antagonist in the rectum. According to the present invention, this is achieved by virtually completely liberating the opioid antagonist 8 hours, preferably 6 hours after oral administration of the pharmaceutical composition (or in the presence of a physiological saline solution), i. already released when the pharmaceutical composition reaches the rectum.
- the opioid antagonist is already released when the pharmaceutical composition reaches the end of the transverse colon or the beginning of the descending colon. According to the invention this is achieved by the opioid antagonist is almost completely released 8 hours, preferably 6 hours after oral administration of the pharmaceutical composition (or in the presence of a physiological saline solution), that is already released when the pharmaceutical composition after about 10 hours this Reached section of the digestive system.
- the antagonist If the antagonist is released in the rectum, it becomes fully effective bypassing the first-pass effect and causes general and local withdrawal. Since an opioid antagonist in the colon can trigger severe diarrhea in opioid-dependent patients, it is furthermore advantageous to suppress release in this section of the digestive tract as far as possible. According to the invention, this is achieved by the opioid antagonist almost completely liberated 8 hours, preferably 6 hours after oral administration of the pharmaceutical composition (or in the presence of a physiological saline solution), that is already released when the pharmaceutical composition after about 6 hours the Colon reached.
- naloxone is continuous, i. is retarded, follows a kinetics approximately first order and virtually no release peaks (peaks) occur.
- the first and second particles in which the opioid or the opioid antagonist is contained by optically detectable properties such as, for example, color, shape or size, or physically measurable properties, such as, for example, weight or density
- optically detectable properties such as, for example, color, shape or size
- physically measurable properties such as, for example, weight or density
- a very similar size of the particles prevents separation by sieving.
- a very similar weight or a very similar density prevents separation due to different floating properties (skimming).
- Valoron ® N solution contains 4 mg of naloxone and 50 mg of tilidine in 0.72 ml, ie in a ratio of 1: 12.5.
- Suboxone ® contains 2 mg naloxone and 8 mg buprenorphine, ie a ratio of 1: 4. It has been shown, however, that in non-opioid-dependent patients, 0.4 mg naloxone is sufficient to cause discrete withdrawal symptoms when intravenously administered with 200 mg morphine, ie at a ratio of naloxone to morphine of 1: 500.
- a ratio of 1: 100 is regarded as optimal, ie withdrawal symptoms are triggered with iv administration without life-threatening conditions occurring.
- Figure 1 is a graphical representation of the release data of naloxone over the
- the pharmaceutical composition comprises a mixture of morphine and naloxone beads.
- Each bead contains a core to which the active agent, i. either morphine or naloxone, and a drug release control coating.
- spherical pellets (sugar spheres) are film-coated using a suspension containing morphine sulfate, povidone (Kollidon K 25) and titanium dioxide in purified water.
- the morphine-loaded pellets are then sprayed with a dispersion of colloidal anhydrous silica (Aerosil 200) in purified water.
- a first release-delaying layer is applied.
- the pellets are film-coated using an Eudragit coating suspension I containing talc and Eudragit FS 30 D in purified water.
- a second release-delaying layer is applied.
- hy- limellose is dispersed in purified water and polysorbate 80 is added.
- talc talc
- titanium dioxide talc
- Eudragit NE 30 D and Eudragit FS 30 D are added.
- this Eudragit coating suspension II the pellets are film-coated. Onto this layer is then sprayed a dispersion of colloidal anhydrous silica.
- spherical pellets (sugar spheres) are film-coated using a suspension containing naloxone hydrochloride dihydrate, povidone (Kollidon K 25) and titania in purified water. These naloxone-loaded pellets are then sprayed with a dispersion of colloidal anhydrous silica (Aerosil 200).
- a release delaying layer is applied.
- hy- limellose is dispersed in purified water and polysorbate 80 is added.
- talc talc
- titanium dioxide talc
- Eudragit NE 30 D and Eudragit FS 30 D are added.
- this Eudragit coating suspension the pellets are film-coated.
- Onto this layer is then sprayed a dispersion of colloidal anhydrous silica onto the pellets. The ratio of the constituents of the coating is adjusted so that the desired release profile is achieved.
- Table 1 shows that the morphine and naloxone beads have very similar properties in terms of, for example, size (radius), density and weight.
- Table 2 and Figure 1 show the course of the release of naloxone over a period of 360 minutes after various storage conditions.
- naloxone starts between 30 and 60 minutes and is practically complete after about 270 to 300 minutes (4.5 to 5 hours). It runs continuously over the entire period without occurrence of peaks (FIG. 1).
- Table 3 shows the time course of the release of naloxone and morphine.
- the pellets contained naloxone (hydrochloride dihydrate) in an amount of 1.2 to 2.1 mg / 2 g or morphine (sulfate pentahydrate) in an amount of 120 to 210 mg morphine / 2 g.
- naloxone While the release of naloxone after 6 hours is not less than 90%, about 30-70% of morphine is released after 8 hours, and a morphine release of not less than 90% is achieved after 20 hours.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/265,860 US20120040009A1 (en) | 2009-04-22 | 2010-04-22 | Particulate pharmaceutical composition with an opioid and an opioid antagonist |
EP10723484A EP2421515A2 (de) | 2009-04-22 | 2010-04-22 | Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten |
AU2010238925A AU2010238925A1 (en) | 2009-04-22 | 2010-04-22 | Particulate pharmaceutical composition having an opioid and an opioid antagonist |
JP2012506335A JP2012524732A (ja) | 2009-04-22 | 2010-04-22 | オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物 |
EA201171271A EA201171271A1 (ru) | 2009-04-22 | 2010-04-22 | Фармацевтическая композиция в форме частиц с опиоидом и антагонистом опиоида |
CA2759870A CA2759870A1 (en) | 2009-04-22 | 2010-04-22 | Particulate pharmaceutical composition with an opioid and an opioid antagonist |
IL215813A IL215813A0 (en) | 2009-04-22 | 2011-10-23 | Pariticulate pharmaceutical composition with an opioid and an opioid antagonist |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102009018474 | 2009-04-22 | ||
DE102009018474.0 | 2009-04-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010121600A2 true WO2010121600A2 (de) | 2010-10-28 |
WO2010121600A3 WO2010121600A3 (de) | 2011-10-27 |
Family
ID=42651253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2010/000453 WO2010121600A2 (de) | 2009-04-22 | 2010-04-22 | Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten |
Country Status (8)
Country | Link |
---|---|
US (1) | US20120040009A1 (de) |
EP (1) | EP2421515A2 (de) |
JP (1) | JP2012524732A (de) |
AU (1) | AU2010238925A1 (de) |
CA (1) | CA2759870A1 (de) |
EA (1) | EA201171271A1 (de) |
IL (1) | IL215813A0 (de) |
WO (1) | WO2010121600A2 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012052169A3 (de) * | 2010-10-21 | 2012-07-26 | Phoeme Gmbh | Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten |
EP2606879A1 (de) | 2011-12-21 | 2013-06-26 | Hexal AG | Multipartikuläre Tablette enthaltend ein Opioid |
WO2016091805A3 (de) * | 2014-12-08 | 2016-12-15 | Develco Pharma Schweiz Ag | Naloxon-monopräparat und mehrschichttablette |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
SG11202100580UA (en) | 2018-07-23 | 2021-02-25 | Trevi Therapeutics Inc | Treatment of chronic cough, breathlessness and dyspnea |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007082935A1 (de) | 2006-01-19 | 2007-07-26 | Phoenux Ag | Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2226933T3 (es) * | 1999-11-01 | 2005-04-01 | John Rhodes | Composicion para tratar el estreñimiento y el sindrome del intestino irritable. |
ES2539904T3 (es) * | 2000-02-08 | 2015-07-07 | Euro-Celtique S.A. | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas |
US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
TWI347201B (en) * | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
EP1897544A1 (de) * | 2006-09-05 | 2008-03-12 | Holger Lars Hermann | Opioid agonist und antagonisten Kombinationen |
-
2010
- 2010-04-22 WO PCT/DE2010/000453 patent/WO2010121600A2/de active Application Filing
- 2010-04-22 JP JP2012506335A patent/JP2012524732A/ja not_active Withdrawn
- 2010-04-22 EA EA201171271A patent/EA201171271A1/ru unknown
- 2010-04-22 US US13/265,860 patent/US20120040009A1/en not_active Abandoned
- 2010-04-22 EP EP10723484A patent/EP2421515A2/de not_active Withdrawn
- 2010-04-22 CA CA2759870A patent/CA2759870A1/en not_active Abandoned
- 2010-04-22 AU AU2010238925A patent/AU2010238925A1/en not_active Abandoned
-
2011
- 2011-10-23 IL IL215813A patent/IL215813A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007082935A1 (de) | 2006-01-19 | 2007-07-26 | Phoenux Ag | Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen |
Non-Patent Citations (1)
Title |
---|
HALBSGUTH U; RENTSCH KM; EICH-HÖCHLI D; DITERICH I; FATTINGER K., BR J CLIN PHARMACOL, vol. 66, 2008, pages 781 - 91 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012052169A3 (de) * | 2010-10-21 | 2012-07-26 | Phoeme Gmbh | Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten |
EP2606879A1 (de) | 2011-12-21 | 2013-06-26 | Hexal AG | Multipartikuläre Tablette enthaltend ein Opioid |
WO2013092589A1 (en) | 2011-12-21 | 2013-06-27 | Hexal Ag | Multiple unit pellet tablet formulation comprising an opioid |
WO2016091805A3 (de) * | 2014-12-08 | 2016-12-15 | Develco Pharma Schweiz Ag | Naloxon-monopräparat und mehrschichttablette |
Also Published As
Publication number | Publication date |
---|---|
EP2421515A2 (de) | 2012-02-29 |
US20120040009A1 (en) | 2012-02-16 |
AU2010238925A1 (en) | 2011-12-15 |
EA201171271A1 (ru) | 2012-05-30 |
IL215813A0 (en) | 2012-01-31 |
WO2010121600A3 (de) | 2011-10-27 |
CA2759870A1 (en) | 2010-10-28 |
JP2012524732A (ja) | 2012-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010121600A2 (de) | Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten | |
DE69834268T2 (de) | Peroral zu verabreichende Arzneiform enthaltend eine Kombination von einem Opioid Agonisten und Naltrexon | |
WO2012052169A2 (de) | Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten | |
DE60216078T2 (de) | Opioid enthaltende arzneiform gegen missbrauch | |
KR100417490B1 (ko) | 오피오이드 제형의 남용을 방지하는 방법 | |
JP4522652B2 (ja) | 乱用防止制御放出オピオイド投薬形態 | |
DE69720985T3 (de) | Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung | |
US20160058755A1 (en) | Pharmaceutical Composition | |
BRPI0618502A2 (pt) | forma farmacêutica oral de micropartìculas contra mau uso | |
WO1998025613A2 (de) | Opioidantagonisthaltige galenische formulierung | |
DE19901687A1 (de) | Opioide Analgetika mit kontrollierter Wirkstofffreisetzung | |
CA2709905A1 (en) | Abuse-resistant oxycodone composition | |
EP2224915A1 (de) | Pharmazeutische zusammensetzung | |
EP1976524B1 (de) | Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen | |
EP1897544A1 (de) | Opioid agonist und antagonisten Kombinationen | |
AU2008338439A1 (en) | Pharmaceutical composition | |
DE102010048883A1 (de) | Verwendung von Buprenorphin zum Abususschutz von Opiat-Vollagonisten sowie entsprechende pharmazeutische Zusammensetzungen | |
AU2004205244B2 (en) | Opioid Agonist/Antagonist Combinations | |
AU2014216032A1 (en) | Pharmaceutical composition | |
DE4423416A1 (de) | Orales pharmazeutisches Präparat für die Schmerztherapie | |
MXPA00006259A (en) | Opioid agonist/antagonist combinations | |
CZ20002359A3 (cs) | Způsob snížení schopnosti opioidního analgetika vyvolat závislost | |
MXPA00006261A (en) | A method of preventing abuse of opioid dosage forms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10723484 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012506335 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13265860 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 215813 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2759870 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010723484 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: a201113307 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12466 Country of ref document: GE Ref document number: 201171271 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010238925 Country of ref document: AU Ref document number: 596574 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2010238925 Country of ref document: AU Date of ref document: 20100422 Kind code of ref document: A |